{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:04Z","timestamp":1794047404223,"version":"4.8.0"},"reference-count":51,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Sickle cell disease (SCD) is an inherited red blood cell disorder that occurs worldwide. Acute vaso-occlusive crisis is the main cause of hospitalization in patients with SCD. There is growing evidence that inflammatory vasculopathy plays a key role in both acute and chronic SCD-related clinical manifestations. In a humanized mouse model of SCD, we found an increase of von Willebrand factor activity and a reduction in the ratio of a disintegrin and metalloproteinase with thrombospondin type 1 motif, number 13 (ADAMTS13) to von Willebrand factor activity similar to that observed in the human counterpart. Recombinant ADAMTS13 was administered to humanized SCD mice before they were subjected to hypoxia\/reoxygenation (H\/R) stress as a model of vaso-occlusive crisis. In SCD mice, recombinant ADAMTS13 reduced H\/R-induced hemolysis and systemic and local inflammation in lungs and kidneys. It also diminished H\/R-induced worsening of inflammatory vasculopathy, reducing local nitric oxidase synthase expression. Collectively, our data provide for the firsttime evidence that pharmacological treatment with recombinant ADAMTS13 (TAK-755) diminished H\/R-induced sickle cell-related organ damage. Thus, recombinant ADAMTS13 might be considered as a potential effective disease-modifying treatment option for sickle cell-related acute events.<\/jats:p>","DOI":"10.3324\/haematol.2021.280233","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T03:29:21Z","timestamp":1650511761000},"page":"2650-2660","source":"Crossref","is-referenced-by-count":22,"title":["Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease"],"prefix":"10.3324","volume":"107","author":[{"given":"Paolo","family":"Rossato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Federti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Matte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Glantschnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Canneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sogue","family":"Coulibaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Schrenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Voelkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dockal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Plaimauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immacolata","family":"Andolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Iolascon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanspeter","family":"Rottensteiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Gritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Scheiflinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Hoellriegl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia De","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"41265","doi-asserted-by":"crossref","unstructured":"Rodday AM, Esham KS, Savidge N, Parsons SK. Patterns of healthcare utilization among patients with sickle cell disease hospitalized with pain crises. EJHaem. 2020; 1(2):438-447.","DOI":"10.1002\/jha2.84"},{"key":"41266","doi-asserted-by":"crossref","unstructured":"Shah N, Bhor M, Xie L, Paulose J, Yuce H. Sickle cell disease complications: Prevalence and resource utilization. PLoS One. 2019; 14(7):e0214355.","DOI":"10.1371\/journal.pone.0214355"},{"key":"41267","doi-asserted-by":"crossref","unstructured":"Desai RJ, Mahesri M, Globe D. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries. Ann Hematol. 2020; 99(11):2497-2505.","DOI":"10.1007\/s00277-020-04233-w"},{"key":"41268","doi-asserted-by":"crossref","unstructured":"Matte A, Recchiuti A, Federti E. Resolution of sickle cell disease-associated inflammation and tissue damage with 17R-resolvin D1. Blood. 2019; 133(3):252-265.","DOI":"10.1182\/blood-2018-07-865378"},{"key":"41269","doi-asserted-by":"crossref","unstructured":"Matte A, Cappellini MD, Iolascon A, Enrica F, De Franceschi L. Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment?. Expert Opin Investig Drugs. 2020; 29(1):23-31.","DOI":"10.1080\/13543784.2020.1703947"},{"key":"41270","doi-asserted-by":"crossref","unstructured":"Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013; 122(24):3892-3898.","DOI":"10.1182\/blood-2013-05-498311"},{"key":"41271","doi-asserted-by":"crossref","unstructured":"Vinchi F, De Franceschi L, Ghigo A. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation. 2013; 127(12):1317-1329.","DOI":"10.1161\/CIRCULATIONAHA.112.130179"},{"key":"41272","doi-asserted-by":"crossref","unstructured":"Matte A, Zorzi F, Mazzi F. New therapeutic options for the treatment of sickle cell disease. Mediterr J Hematol Infect Dis. 2019; 11(1):e2019002.","DOI":"10.4084\/mjhid.2019.002"},{"key":"41273","doi-asserted-by":"crossref","unstructured":"De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. Semin Thromb Hemost. 2011; 37(3):226-236.","DOI":"10.1055\/s-0031-1273087"},{"key":"41274","unstructured":"De Franceschi L, Corrocher R. Established and experimental treatments for sickle cell disease. Haematologica. 2004; 89(3):348-356."},{"key":"41275","doi-asserted-by":"crossref","unstructured":"Lombardi E, Matte A, Risitano AM. Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. Haematologica. 2019; 104(5):919-928.","DOI":"10.3324\/haematol.2018.198622"},{"key":"41276","doi-asserted-by":"crossref","unstructured":"Faes C, Ilich A, Sotiaux A. Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. Blood. 2019; 133(23):2529-2541.","DOI":"10.1182\/blood.2019000424"},{"key":"41277","doi-asserted-by":"crossref","unstructured":"Noubouossie D, Key NS, Ataga KI. Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev. 2016; 30(4):245-256.","DOI":"10.1016\/j.blre.2015.12.003"},{"key":"41278","doi-asserted-by":"crossref","unstructured":"Faes C, Sparkenbaugh EM, Pawlinski R. Hypercoagulable state in sickle cell disease. Clin Hemorheol Microcirc. 2018; 68(2-3):301-318.","DOI":"10.3233\/CH-189013"},{"key":"41279","doi-asserted-by":"crossref","unstructured":"Kawecki C, Lenting PJ, Denis CV. von Willebrand factor and inflammation. J Thromb Haemost. 2017; 15(7):1285-1294.","DOI":"10.1111\/jth.13696"},{"key":"41280","doi-asserted-by":"crossref","unstructured":"Gragnano F, Sperlongano S, Golia E. The role of von Willebrand factor in vascular inflammation: from pathogenesis to targeted therapy. Mediators Inflamm. 2017; 2017:5620314.","DOI":"10.1155\/2017\/5620314"},{"key":"41281","doi-asserted-by":"crossref","unstructured":"Dalle Carbonare L, Matte A, Valenti MT. Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease. Blood. 2015; 126(20):2320-2328.","DOI":"10.1182\/blood-2015-04-641969"},{"key":"41282","doi-asserted-by":"crossref","unstructured":"Schwameis M, Schorgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost. 2015; 113(4):708-718.","DOI":"10.1160\/TH14-09-0731"},{"key":"41283","doi-asserted-by":"crossref","unstructured":"Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017; 129(21):2836-2846.","DOI":"10.1182\/blood-2016-10-709857"},{"key":"41284","doi-asserted-by":"crossref","unstructured":"Scully M, Knobl P, Kentouche K. Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood. 2017; 130(19):2055-2063.","DOI":"10.1182\/blood-2017-06-788026"},{"key":"41285","doi-asserted-by":"crossref","unstructured":"Zhou Z, Behymer M, Guchhait P. Role of extracellular hemoglobin in thrombosis and vascular occlusion in patients with sickle cell anemia. Anemia. 2011; 2011:918916.","DOI":"10.1155\/2011\/918916"},{"key":"41286","doi-asserted-by":"crossref","unstructured":"Zhou Z, Han H, Cruz MA. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost. 2009; 101(6):1070-1077.","DOI":"10.1160\/TH08-10-0677"},{"key":"41287","doi-asserted-by":"crossref","unstructured":"Zhou Z, Yee DL, Guchhait P. Molecular link between intravascular hemolysis and vascular occlusion in sickle cell disease. Curr Vasc Pharmacol. 2012; 10(6):756-761.","DOI":"10.2174\/157016112803520738"},{"key":"41288","doi-asserted-by":"crossref","unstructured":"Schnog JJ, Kremer Hovinga JA, Krieg S. ADAMTS13 activity in sickle cell disease. Am J Hematol. 2006; 81(7):492-498.","DOI":"10.1002\/ajh.20653"},{"key":"41289","doi-asserted-by":"crossref","unstructured":"Novelli EM, Kato GJ, Hildesheim ME. Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease. Haematologica. 2013; 98(11):e132-134.","DOI":"10.3324\/haematol.2013.092635"},{"key":"41290","doi-asserted-by":"crossref","unstructured":"Chen J, Hobbs WE, Le J. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood. 2011; 117(13):3680-3683.","DOI":"10.1182\/blood-2010-08-302539"},{"key":"41291","doi-asserted-by":"crossref","unstructured":"Colombatti R, De Bon E, Bertomoro A. Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. PLoS One. 2013; 8(10):e78801.","DOI":"10.1371\/journal.pone.0078801"},{"key":"41292","doi-asserted-by":"crossref","unstructured":"Sins JWR, Schimmel M, Luken BM. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state. J Thromb Haemost. 2017; 15(7):1392-1402.","DOI":"10.1111\/jth.13728"},{"key":"41293","doi-asserted-by":"crossref","unstructured":"Kalish BT, Matte A, Andolfo I. Dietary omega-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease. Haematologica. 2015; 100(7):870-880.","DOI":"10.3324\/haematol.2015.124586"},{"key":"41294","doi-asserted-by":"crossref","unstructured":"Chauhan AK, Motto DG, Lamb CB. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006; 203(3):767-776.","DOI":"10.1084\/jem.20051732"},{"key":"41295","unstructured":"Rossato P, Canneva F, Schrenk G. Dose-dependent effects of recombinant ADAMTS13 (TAK-755\/SHP655) on recovery in a humanized mouse model of sickle cell disease. Res Pract Thromb Haemost. 2019; 3(Suppl 1):PB1593."},{"key":"41296","unstructured":"de Franceschi L, Turrini F, Honczarenko M. In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica. 2004; 89(11):1287-1298."},{"key":"41297","doi-asserted-by":"crossref","unstructured":"De Franceschi L, Olivieri O, Miraglia del Giudice E. Membrane cation and anion transport activities in erythrocytes of hereditary spherocytosis: effects of different membrane protein defects. Am J Hematol. 1997; 55(3):121-128.","DOI":"10.1002\/(SICI)1096-8652(199707)55:3<121::AID-AJH1>3.0.CO;2-U"},{"key":"41298","doi-asserted-by":"crossref","unstructured":"Brugnara C, de Franceschi L. Effect of cell age and phenylhydrazine on the cation transport properties of rabbit erythrocytes. J Cell Physiol. 1993; 154(2):271-280.","DOI":"10.1002\/jcp.1041540209"},{"key":"41299","doi-asserted-by":"crossref","unstructured":"Park SY, Matte A, Jung Y. Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion. Blood. 2020; 135(23):2071-2084.","DOI":"10.1182\/blood.2019002227"},{"key":"41300","doi-asserted-by":"crossref","unstructured":"Sabaa N, de Franceschi L, Bonnin P. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest. 2008; 118(5):1924-1933.","DOI":"10.1172\/JCI33308"},{"key":"41301","doi-asserted-by":"crossref","unstructured":"de Franceschi L, Baron A, Scarpa A. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia\/reoxygenation. Blood. 2003; 102(3):1087-1096.","DOI":"10.1182\/blood-2002-07-2135"},{"key":"41302","doi-asserted-by":"crossref","unstructured":"Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood. 2004; 103(2):607-612.","DOI":"10.1182\/blood-2003-08-2861"},{"key":"41303","doi-asserted-by":"crossref","unstructured":"Demagny J, Driss A, Stepanian A. ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso-occlusive crisis of sickle cell disease. Res Pract Thromb Haemost. 2021; 5(1):197-203.","DOI":"10.1002\/rth2.12460"},{"key":"41304","doi-asserted-by":"crossref","unstructured":"Nwankwo JO, Gremmel T, Gerrits AJ. Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease. Thromb Res. 2017; 160:58-65.","DOI":"10.1016\/j.thromres.2017.10.018"},{"key":"41305","doi-asserted-by":"crossref","unstructured":"Federti E, Matte A, Ghigo A. Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension. Free Radic Biol Med. 2017; 112:376-386.","DOI":"10.1016\/j.freeradbiomed.2017.08.004"},{"key":"41306","doi-asserted-by":"crossref","unstructured":"De Franceschi L, Platt OS, Malpeli G. Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice. FASEB J. 2008; 22(6):1849-1860.","DOI":"10.1096\/fj.07-098921"},{"key":"41307","doi-asserted-by":"crossref","unstructured":"Heusch G. Critical Issues for the Translation of Cardioprotection. Circ Res. 2017; 120(9):1477-1486.","DOI":"10.1161\/CIRCRESAHA.117.310820"},{"key":"41308","doi-asserted-by":"crossref","unstructured":"Tang L, Wang H, Ziolo MT. Targeting NOS as a therapeutic approach for heart failure. Pharmacol Ther. 2014; 142(3):306-315.","DOI":"10.1016\/j.pharmthera.2013.12.013"},{"key":"41309","doi-asserted-by":"crossref","unstructured":"Golbidi S, Badran M, Ayas N, Laher I. Cardiovascular consequences of sleep apnea. Lung. 2012; 190(2):113-132.","DOI":"10.1007\/s00408-011-9340-1"},{"key":"41310","doi-asserted-by":"crossref","unstructured":"Naik RP, Derebail VK. The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait. Expert Rev Hematol. 2017; 10(12):1087-1094.","DOI":"10.1080\/17474086.2017.1395279"},{"key":"41311","doi-asserted-by":"crossref","unstructured":"Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol. 2015; 11(3):161-171.","DOI":"10.1038\/nrneph.2015.8"},{"key":"41312","doi-asserted-by":"crossref","unstructured":"Martinelli N, Montagnana M, Pizzolo F. A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19. Thromb Res. 2020; 193:170-172.","DOI":"10.1016\/j.thromres.2020.07.034"},{"key":"41313","doi-asserted-by":"crossref","unstructured":"Zhou XJ, Laszik Z, Ni Z. Down-regulation of renal endothelial nitric oxide synthase expression in experimental glomerular thrombotic microangiopathy. Lab Invest. 2000; 80(7):1079-1087.","DOI":"10.1038\/labinvest.3780113"},{"key":"41314","doi-asserted-by":"crossref","unstructured":"Torres L, Conran N. Emerging pharmacotherapeutic approaches for the management of sickle cell disease. Expert Opin Pharmacother. 2019; 20(2):173-186.","DOI":"10.1080\/14656566.2018.1548610"},{"key":"41315","doi-asserted-by":"crossref","unstructured":"Kopic A, Benamara K, Piskernik C. Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2016; 14(7):1410-1419.","DOI":"10.1111\/jth.13341"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280233\/74360","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280233\/74976","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10605\/74360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:01:31Z","timestamp":1794045691000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.280233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":51,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,10,31]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.280233","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,21]]}}}